These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 8120858

  • 21. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC.
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Bone mineral density and depot medroxyprogesterone acetate.
    Albertazzi P, Bottazzi M, Steel SA.
    Contraception; 2006 Jun; 73(6):577-83. PubMed ID: 16730487
    [Abstract] [Full Text] [Related]

  • 24. Estrogen dose in oral contraceptives: FDA committee examines safety and utility of 50 mcg estrogen OCs.
    Contracept Rep; 1994 Mar; 5(1):10-3. PubMed ID: 12287738
    [Abstract] [Full Text] [Related]

  • 25. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism.
    Gambacciani M, Spinetti A, Taponeco F, Cappagli B, Piaggesi L, Fioretti P.
    Obstet Gynecol; 1994 Mar; 83(3):392-6. PubMed ID: 8127531
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Contraception without risk of breast disease: epidemiologic and physiopathologic arguments].
    Le Coutour X.
    NPN Med; 1985 Apr 02; 5(88):471-6. PubMed ID: 12315304
    [Abstract] [Full Text] [Related]

  • 28. [Oral contraception: disadvantages of estrogen reduction].
    Denis C.
    Contracept Fertil Sex (Paris); 1993 Jun 02; 21(6):481-8. PubMed ID: 12318238
    [Abstract] [Full Text] [Related]

  • 29. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M.
    Br J Fam Plann; 1999 Jul 02; 25(2):69-76. PubMed ID: 10454658
    [Abstract] [Full Text] [Related]

  • 30. [Oral contraception: evolution of concepts over the last thirty years].
    Belaisch J, Hommais-loufrani B.
    Contracept Fertil Sex (Paris); 1987 Nov 02; 15(11 Suppl):1-8. PubMed ID: 12281408
    [Abstract] [Full Text] [Related]

  • 31. Oral contraceptive risks: a realistic appraisal.
    Bressler R, Durand JL.
    Drug Ther (NY); 1979 Oct 02; 9(10):81-95. PubMed ID: 12279276
    [Abstract] [Full Text] [Related]

  • 32. Dispelling OC myths and misperceptions.
    Grimes DA.
    Dialogues Contracept; 1994 Oct 02; 4(3):1-4. PubMed ID: 12345574
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Oral contraceptives and MI: how strong is the link?
    Jick H.
    J Cardiovasc Med; 1982 May 15; 7(5):481, 484-5. PubMed ID: 12311565
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Oral contraceptives and cancer of the reproductive organs.
    Huezo C.
    IPPF Med Bull; 1985 Dec 15; 19(6):3-4. PubMed ID: 12267511
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Hypertension, heart disease and combined oral contraceptives].
    Lombrail P, Cathelineau G.
    Contracept Fertil Sex (Paris); 1985 Jan 15; 13(1 Suppl):127-30. PubMed ID: 12280198
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.